Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Baxter Healthcare Corporation Cerus Corporation |
---|---|
Information provided by: | Baxter Healthcare Corporation |
ClinicalTrials.gov Identifier: | NCT00261924 |
Objective: To determine if platelets treated for pathogen inactivation and stored for 6 to 7 days are safe and effective compared to platelets collected by the same method, stored for the same amount of time and not treated for pathogen inactivation.
Condition | Intervention | Phase |
---|---|---|
Thrombocytopenia |
Procedure: Platelet transfusion |
Phase IV |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Active Control, Parallel Assignment |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Clinical Registration | CDE ClinRegistration@baxter.com |
United Kingdom | |
SNBTS National Science Laboratory, Edinburgh and Western General Hospital | Recruiting |
Edinburgh, United Kingdom |
Study Director: | Jocelyne Flament, M.D. | Baxter Healthcare Corporation |
Study ID Numbers: | 451-P-A-NIV |
Study First Received: | December 5, 2005 |
Last Updated: | August 9, 2006 |
ClinicalTrials.gov Identifier: | NCT00261924 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Thrombocytopenic patients |
Thrombocytopathy Thrombocytopenia Hematologic Diseases Blood Platelet Disorders |